

Jenner & Block Is First Law Firm Accredited with CEO Cancer Gold Standard

1/12/2007

The CEO Roundtable on Cancer, Inc. announced this week that Jenner & Block has been accredited with the CEO Cancer Gold Standard(TM), a workplace initiative that combats cancer through employee programs encouraging risk reduction, early detection and quality care. Jenner & Block is the first law firm to receive the recognition, which was initiated by CEO Roundtable in 2001.

Jenner & Block was honored with the Gold Standard for offering a number of progressive benefits and programs that lower the risk of cancer through lifestyle changes. Some of these benefits include coverage for preventative screenings to detect cancers at the earliest possible stage, providing access to the best-available treatments and clinical trials for affected employees and/or family members, and on-site courses and resources for tobacco cessation, diet and nutrition, and physical activity.

"One of our core values is respecting our people, and promoting a healthy lifestyle for our workforce is a natural outgrowth of that commitment," said Jenner & Block Managing Partner Gregory S. Gallopoulos.

The CEO Roundtable on Cancer consists of CEOs from diverse industries who have pledged to fight cancer in workplaces across the United States. The group was formed after President George H. W. Bush challenged a group of leading executives to do something "bold" to combat cancer in corporate America. The group has since collaborated with the American Cancer Society to encourage its widespread adoption in workplaces across the country.

"We know that at least half of all cancer deaths can be prevented," said John R. Seffrin, Ph.D., chief executive officer of the American Cancer Society, in a statement. "By creating a healthier workplace and becoming an accredited organization, everyone benefits."

Other companies accredited for their special anti-cancer employee programs include; American Legacy Foundation, AstraZeneca, Enzon Pharmaceuticals, GlaxoSmithKline, Johnson & Johnson, MD Anderson Cancer Center, Novartis, OSI Pharmaceuticals, SAS Institute and Quintiles Transnational Corp.